Evicenter
Cobenfy (xanomeline and trospium chloride) in Schizophrenia
Manufacturer
Bristol-Myers Squibb Company
Prescribing information
Cobenfy (opens in a new tab)
Questions
38
Last updated

All questions

Clinical trials: Cobenfy (xanomeline and trospium chloride) in schizophrenia

4 questions · 4 sources

Study results

How effective was COBENFY for schizophrenia in clinical trials?

“In Study 1 and Study 2, patients randomized to COBENFY showed a statistically significant reduction from baseline to Week 5 in the PANSS Total Score compared to the placebo group. The results of Studies 1 and 2 are shown in Table 4. A secondary endpoint, the change from baseline to Week 5 on the Clinical Global Impression–Severity (CGI-S) score, was statistically significant for COBENFY compared to placebo in Study 1. The CGI-S is a validated clinician-rated scale that measures the patient’s current illness state and overall clinical state on a 1 (normal, not at all ill) to 7-point (extremely ill) scale. Examination of subgroups by age, sex, and race did not suggest differences in response in the study (there were no patients over 65 years of age). Table 4: Primary Efficacy Results for Change from Baseline in PANSS Total Score at Week 5 in Adults with Schizophrenia (Studies 1 and 2) Primary Efficacy Endpoint: PANSS Total Score Study Number Treatment Group N Mean Baseline Score (SD) LS Mean Change from Baseline (SE) Placebo-subtracted Difference (95% CI) a 1 COBENFY 117 98.2 (8.9) -21.2 (1.7) -9.6 (-13.9, -5.2)* Placebo 119 97.7 (9.4) -11.6 (1.6) 2 COBENFY 114 96.9 (8.8) -20.6 (1.6) -8.4 (-12.4, -4.3)* Placebo 120 96.5 (8.8) -12.2 (1.6) The PANSS Total Score may range from 30 to 210; higher scores reflect greater symptom severity. SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval. a Difference (drug minus placebo) in LS mean change from baseline. * Statistically significantly superior to placebo.” (opens the source at this quote in a new tab)

Note: The prescribing information identifies the two placebo-controlled trials as Study 1 (NCT04659161) and Study 2 (NCT04738123).

Clinical trials

How were the 5-week COBENFY EMERGENT trials designed?

What were the long-term COBENFY trials (EMERGENT-4 and EMERGENT-5)?

“Two 52-week open-label studies evaluated long-term safety and efficacy4,5 Two long-term, 52-week, phase 3, open-label studies4,5,7 EMERGENT-4 included patients who previously completed the treatment period of EMERGENT-2 or EMERGENT-34 EMERGENT-5 included a patient population with the following select characteristics7: Aged 18 to 65 years at time of screening No psychiatric hospitalization, acute crisis intervention, or other inpatient care within 8 weeks prior to screening PANSS score of ≤80 CGI-S score of ≤4 Received an oral antipsychotic medication within 30 days prior to screening Antipsychotic down-taper, if clinically appropriate in the opinion of the investigator, may occur during the screening phase The primary objective of these studies was to assess the long-term safety and tolerability of COBENFY4,5 The secondary objective was to assess the long-term efficacy and evaluate plasma concentrations of xanomeline and trospium chloride after administration of COBENFY7 Patients with a history of treatment resistance to antipsychotic medications were excluded from these trials6,7,¶ Failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) within the past 12 months or having received clozapine within the past year (for EMERGENT-4) or 3 years (for EMERGENT-5).7” (opens the source at this quote in a new tab)

What was COBENFY adherence in the 52-week EMERGENT-5 outpatient trial?